Recent advances in tumor targeting via EPR effect for cancer treatment
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent
in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy …
in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy …
Biodegradable polymeric nanoparticles for drug delivery to solid tumors
Advances in nanotechnology have favored the development of novel colloidal formulations
able to modulate the pharmacological and biopharmaceutical properties of drugs. The …
able to modulate the pharmacological and biopharmaceutical properties of drugs. The …
Nanomedicine-based commercial formulations: Current developments and future prospects
Background In recent decades, there has been a considerable increase in the number of
nanomedicine-based formulations, and their advantages, including controlled/targeted drug …
nanomedicine-based formulations, and their advantages, including controlled/targeted drug …
Nanoparticle-based medicines in clinical cancer therapy
S Wang, K Cheng, K Chen, C Xu, P Ma, G Dang… - Nano Today, 2022 - Elsevier
Anti-cancer drugs with various mechanisms emerge in succession, but most of free
therapeutics are accompanied by some disadvantages, such as poor safety and …
therapeutics are accompanied by some disadvantages, such as poor safety and …
Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer
In tumorous tissues, the absence of vasculature supportive tissues intimates the formation of
leaky vessels and pores (100 nm to 2 μm in diameter) and the poor lymphatic system offers …
leaky vessels and pores (100 nm to 2 μm in diameter) and the poor lymphatic system offers …
[HTML][HTML] Applications of nanoparticle systems in drug delivery technology
The development of nanoparticle-based drug formulations has yielded the opportunities to
address and treat challenging diseases. Nanoparticles vary in size but are generally ranging …
address and treat challenging diseases. Nanoparticles vary in size but are generally ranging …
Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date
In this review we provide an up to date snapshot of nanomedicines either currently approved
by the US FDA, or in the FDA clinical trials process. We define nanomedicines as …
by the US FDA, or in the FDA clinical trials process. We define nanomedicines as …
Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release
The development of biodegradable polymers represents a revolution in medicine spanning
over 50 years and leading to significant biotechnological advancements in drug delivery …
over 50 years and leading to significant biotechnological advancements in drug delivery …
Polylactic acid (PLA) controlled delivery carriers for biomedical applications
B Tyler, D Gullotti, A Mangraviti, T Utsuki… - Advanced drug delivery …, 2016 - Elsevier
Polylactic acid (PLA) and its copolymers have a long history of safety in humans and an
extensive range of applications. PLA is biocompatible, biodegradable by hydrolysis and …
extensive range of applications. PLA is biocompatible, biodegradable by hydrolysis and …
[HTML][HTML] Insoluble drug delivery strategies: review of recent advances and business prospects
The emerging trends in the combinatorial chemistry and drug design have led to the
development of drug candidates with greater lipophilicity, high molecular weight and poor …
development of drug candidates with greater lipophilicity, high molecular weight and poor …